4//SEC Filing
Yea Christopher 4
Accession 0001415889-25-022306
CIK 0001348911other
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 4:27 PM ET
Size
11.9 KB
Accession
0001415889-25-022306
Insider Transaction Report
Form 4
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Transactions
- Sale
Common Stock
2025-08-18$13.19/sh−2,649$34,932→ 129,493 total - Exercise/Conversion
Restricted Stock Unit
2025-08-17−1,773→ 5,322 total→ Common Stock (1,773 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-08-17−2,430→ 2,431 total→ Common Stock (2,430 underlying) - Exercise/Conversion
Common Stock
2025-08-17+4,203→ 132,142 total
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date.
- [F4]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001691102
Filing Metadata
- Form type
- 4
- Filed
- Aug 18, 8:00 PM ET
- Accepted
- Aug 19, 4:27 PM ET
- Size
- 11.9 KB